University of Windsor lab uses compound inspired by spider lily to kill cancer cells - Action News
Home WebMail Saturday, November 23, 2024, 04:06 AM | Calgary | -12.0°C | Regions Advertise Login | Our platform is in maintenance mode. Some URLs may not be available. |
Windsor

University of Windsor lab uses compound inspired by spider lily to kill cancer cells

A research team at the University of Windsor has developed a cancer-killing compound inspired by the spider lily. It has targeted and killed 20 varieties of cancer cells so far.

Compound can distinguish between cancerous and healthy cells

A team led by chemistry professor, Siyaram Pandey, has developed a cancer-killing compound from the common spider lily plant. (University of Windsor)

A University of Windsor lab has successfully used a compound inspired by a flower to target and kill cancer.

A team led by chemistry professor Siyaram Pandeyhas discovered a lab-synthesized drug compound based on extract from the common spider lily plant to kill 20 varietiesof cancer cells.

"This drug is very selective and targets the mitochondria of various cancer cells to induce apoptosis, which means the cancer cells commit suicide and the normal cells continue to thrive," explained Pandey. "We are talking about a drug that could be 10 times more effective that the very toxic chemotherapy drug Taxol."

Originally, it tookone kilogram of spider lily buds to make one milligram of the compound, but by teaming up with other Ontario universities a non-toxic, synthetic compound calledpancratistatin was created.

Seven compound variations were produced and patented in cooperation with researchers from McMaster and Brock universities. The team tested the variations on animals with tumours as well as 20 varieties of cancer cells including breast, cancer, prostate, melanoma and bone.

Thecompound is so effective because it targetsthe mitochondriaof cancer cells while leaving healthy cells alone, according to Pandey.

"This is the first time we got a compound which can distinguish between cancer and normal cells," headded.

Before the treatment becomes available to the public a drug company would have to put the compound through clinical trials.